Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ago Ahene"'
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose A population pharmacokinetic (PK) analysis of the anti-fibroblast growth factor receptor 2b antibody, bemarituzumab, was performed to evaluate the impact of covariates on the PK and assess whether dose adjustment is necessary for a future pha
Autor:
Yuying Gao, Lucy Liu, Lyndah Dreiling, Helen Collins, Amy W. Hsu, Ago Ahene, Monica Macal, Hong Xiang
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose To report population pharmacokinetic (PK) analysis of the phase 1 study (FPA144-001, NCT02318329) and to select a clinical dose and schedule that will achieve an empirical target trough concentration (Ctrough) for an anti-fibroblast growth fa
Autor:
Abigael G. Chan, Ago Ahene, Servando Palencia, Rong Deng, Janine Powers, James Zanghi, Amy W. Hsu, David Bellovin, Ursula Jeffry, Hong Xiang, Helen Collins
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Bemarituzumab (FPA144) is a first-in-class, humanized, afucosylated immunoglobulin G1 monoclonal antibody (mAb) directed against fibroblast growth factor receptor 2b (FGFR2b) with two mechanisms of action against FGFR2b-overexpressing tumors: inhibit